Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Passed first chamber: it can still change before the session ends.
- Stage
- Passed first chamber
- Started in
- Senate
- Sponsors
- 16
- Latest action
- Aug 10, 2026
What it does
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a…
Official summary · Reported to Senate · Jul 16, 2026
Titles and provisions can change as the bill moves.
Where it stands
Introduced (Done)
Committee (Done)
Floor (Current step)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.